NYSE:AMCR Amcor Q2 2025 Earnings Report $9.56 -0.10 (-0.98%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Amcor EPS ResultsActual EPS$0.16Consensus EPS $0.16Beat/MissMet ExpectationsOne Year Ago EPS$0.09Amcor Revenue ResultsActual Revenue$3.24 billionExpected Revenue$3.33 billionBeat/MissMissed by -$90.84 millionYoY Revenue Growth-0.30%Amcor Announcement DetailsQuarterQ2 2025Date2/4/2025TimeBefore Market OpensConference Call DateTuesday, February 4, 2025Conference Call Time8:00AM ETUpcoming EarningsAmcor's Q3 2025 earnings is scheduled for Tuesday, April 29, 2025, with a conference call scheduled on Wednesday, April 30, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Amcor Q2 2025 Earnings Call TranscriptProvided by QuartrFebruary 4, 2025 ShareLink copied to clipboard.PresentationSkip to Participants Operator00:00:00Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amcor Half Year Results 2025. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Operator00:00:30Thank you. I would now like to turn the call over to Tracey Whitehead, Head of Investor Relations. Please go ahead. Tracey WhiteheadHead, IR at Amcor00:00:37Thank you, Kate, and thank you everyone for joining Amcor's fiscal 2025 2nd quarter earnings call. Joining today is Peter Konichne, Chief Executive Officer and Michael Casamento, Chief Financial Officer. Before I hand over, let me note a few items. On our website, dotcom, under the Investors section, you'll find today's press release and presentation, which we'll discuss on this call. Please be aware that we will also discuss non GAAP financial measures and related reconciliations can be found in that press release and the presentation. Tracey WhiteheadHead, IR at Amcor00:01:16Remarks will also include forward looking statements that are based on management's current views and assumptions. The second and third slides in today's presentation list several factors that could cause future results to be different than current estimates. Reference can be made to Amcor's SEC filings, including our statements on Form 10 ks and 10 Q for further details. Please note that during the question and answer session, we request that you limit yourself to a single question and then rejoin the queue if you have any additional questions or follow ups. With that, over to you, P. Tracey WhiteheadHead, IR at Amcor00:01:51K. Peter KoniecznyChief Executive Officer at Amcor00:01:52Thank you, Tracy, and thank you to all who have joined us for today's call. Omcor had a very active second quarter and we're progressing well on 3 clear priorities. 1, deliver on the base business 2, complete the work required to close the announced merger with Berry Global and 3, make sure we are well prepared for a fast start and integration. With the base business, we start as always with safety on Slide 4. I'm incredibly proud of the commitment our teams demonstrate to safety every day. Peter KoniecznyChief Executive Officer at Amcor00:02:24The safety and well-being of our people will always be our top priority and we're constantly looking for opportunities to improve. In fiscal 2025 to date, we have continued to deliver outstanding results. We achieved an industry leading total recordable incident rate of 0.30 and 79% of our sites remained injury free for more than a year. Our key messages for today are on Slide 5. Q2 results were in line with expectations we set in October as we continued to execute and deliver across key financial metrics. Peter KoniecznyChief Executive Officer at Amcor00:02:59We are pleased to report our 4th consecutive quarter of sequential volume improvement and a return to sales growth albeit marginal. Margins also continued to improve helping drive a 5% increase in both adjusted EBIT and EPS on a comparable basis. The solid performance along with our confidence in the second half leaves us on track to deliver against our full year guidance which we are reaffirming again today. And finally, as we continue to execute well on the underlying business, we're also highly focused on the unique opportunity we have to accelerate growth and enhance margin enhance earnings and cash generation through the previously announced combination with Berry. Turning to slide 6. Peter KoniecznyChief Executive Officer at Amcor00:03:43On our Q1 earnings call in October, I outlined my strategy for Amgore to deliver consistent sustainable organic growth in the low to mid single digit range through an unwavering focus on our customers on sustainability and on our portfolio mix. I also shared my future vision for Amcor to become the global packaging partner of choice. The merger with Berry is directly aligned with this strategy and moves us further towards our vision. Slide 7 highlights the compelling rationale behind this combination. 1 of the most powerful and transformational long term benefits of this merger is the opportunity to drive stronger, more consistent and sustainable volume driven organic growth and to further improve margins. Peter KoniecznyChief Executive Officer at Amcor00:04:28There are a number of growth unlocks that will become available with 2 of the most significant shown on this slide. First, the combined company will be a better business with a broader primary packaging portfolio at scale across consumer goods and healthcare end markets. In the context of a stronger larger scale company, AMKRE will be uniquely positioned to further refine and prune our portfolio mix to focus even more on attractive higher value faster growing end markets. This journey is already underway with Berry's recent divestitures of its HHNF and Tapes businesses which have significantly enhanced their product mix while reducing cyclicality. As a result of further pruning, we will increase average growth rates, margins and cash generation across the remaining portfolio. Peter KoniecznyChief Executive Officer at Amcor00:05:182nd, this combination creates exceptional capability in material science and innovation. We will drive growth for innovation and more sustainable packaging solutions by effectively and efficiently leveraging our combined resources bringing together more than 1500 R and D professionals and annual R and D investment of $180,000,000 will allow us to optimize and redirect R and D spend providing capacity to focus on solving the most complex functionality and sustainability challenges faced by our customers and consumers. Accelerated growth combined with significant synergies means this combination will drive compelling near and long term value for all shareholders. Moving to Slide 8. You've seen this slide before, but let me recap a few of the drivers behind the significant and sustainable financial value we're creating. Peter KoniecznyChief Executive Officer at Amcor00:06:10We continue to pressure test our assumptions and are confident in the $650,000,000 in total cost growth and financial synergies we've identified and will deliver. We expect to realize 40 percent or $260,000,000 of total synergies in the 1st year and the full run rate in year 3 with an additional $280,000,000 of one time cash benefits from working capital improvements, which will fund cash costs to achieve synergies. Including synergies, this combination is expected to deliver significant cash EPS accretion of over 35% and annual cash flow in excess of $3,000,000,000 This will allow us to maintain a strong investment grade balance sheet and deploy additional cash to invest in organic growth and M and A. We expect to increase long term EPS growth and take the outcomes under our value shareholder value creation model to a new and higher level. Turning to slide 9 and an update on the steps we have taken towards closing. Peter KoniecznyChief Executive Officer at Amcor00:07:13We are moving very quickly from a process perspective to complete the work required to bring the merger to close. On January 23, we filed the definitive joint proxy statement prospectus with the SEC and shareholder meetings are scheduled to take place on February 25. Initial materials required to secure regulatory approvals across nearly all required jurisdictions have been submitted and the first approvals have been received. The composition of the Board of Directors has been finalized and our path to completion is well advanced. From an integration preparedness perspective, we're also well positioned. Peter KoniecznyChief Executive Officer at Amcor00:07:50We are focused on building our teams, filling key roles, ensuring we will make a fast start upon close with clearly defined plans for the 1st 100 days in line with our proven integration playbook. We have a strong track record of successfully executing on large transactions and our teams have significant experience in integrating sizable businesses. Moving to slide 10 for a summary of our financial results. As noted earlier, delivering on the base business is a top priority and we continue to execute well with 2nd quarter results in line with the expectations we outlined in October. Our differentiated value proposition resonates with customers supporting a return to overall sales growth in Q2 as net sales of $3,200,000,000 were slightly ahead of last year. Peter KoniecznyChief Executive Officer at Amcor00:08:38Overall volumes grew by 2.3% improving on the Q1 and offsetting an unfavorable impact of price mix. This was the 4th consecutive quarter of sequential improvement in volumes. As expected, destocking continued in healthcare and demand remained soft in the North American beverage business, impacting mix and unfavorably impacting overall volumes by more than 1%. Across the balance of the business, overall volume growth was consistent with the Q1 up approximately 4%. Improving volume trends and continued proactive cost and productivity actions more than offset unfavorable price mix headwinds leading to another quarter of solid earnings growth. Peter KoniecznyChief Executive Officer at Amcor00:09:18Adjusted EBIT increased by 5% compared with last year and adjusted adjusted EBIT margin expanded by over year over year by 40 basis points. Adjusted earnings per share of $0.1601 also grew by 5% on a comparable basis and cash generation was above the prior year positioning us to reaffirm our fiscal year guidance. I'll now turn the call over to Michael to cover the results and outlook in more detail. Michael CasamentoEVP, Finance & CFO at Amcor00:09:44Thanks, Pekay, and hello, everyone. Beginning with Flexibles segment on Slide 11 and focusing on our fiscal Q2 performance. Q2 volumes were up 3% compared with last year, reflecting ongoing solid growth across all key geographies and a number of important end markets. Net sales also returned to growth increasing by 1% on a comparable constant currency basis and higher volumes more than offset unfavorable price mix of approximately 2% primarily related to lower healthcare volumes. As expected and discussed in prior earnings calls, we continued to see destocking in the healthcare in North America and Europe Pharmaceuticals, which resulted in a headwind of approximately 1% to overall segment volumes. Michael CasamentoEVP, Finance & CFO at Amcor00:10:33Compared to the fiscal Q1, destocking abated and the related price mix headwind improved. And exiting the Q2, we believe Healthcare destocking is now largely behind us. Across the balance of our flexibles portfolio, volumes were up 4% reflecting solid demand across regions and in many product categories. In North America and Europe, 2nd quarter demand remained solid with volumes increasing mid single digits in both regions despite the negative impact of Healthcare destocking. Top line growth was strong across the Asian region reflecting price mix benefits and mid single digit volume growth supported by strong demand in China and across Southeast Asia. Michael CasamentoEVP, Finance & CFO at Amcor00:11:18In Latin America, volumes were broadly in line with last year's Q2 with good growth in Colombia and Peru offset by demand in Argentina. From a product category standpoint, ready meals and premium coffee showed strong growth and dairy, meat, liquids and pet care were up low to mid single digits. In healthcare, medical returned to growth. However, pharma volumes continued to be down low double digits compared with last year as a result of destocking. And as I mentioned earlier is now largely behind us. Michael CasamentoEVP, Finance & CFO at Amcor00:11:51Good earnings leverage continued and adjusted EBIT for the quarter of $322,000,000 grew by 4 percent on a comparable constant currency basis. Higher volumes combined with strong cost performance and the benefits from restructuring led to another quarter of margin expansion with adjusted EBIT margins up 20 basis points to 12.8%. Turning to Rigid Packaging on slide 12. The Rigid business continues to advance its performance and the trajectory of overall segment volumes improved for the 4th consecutive quarter. Net sales were approximately 1% lower than last year reflecting an unfavorable impact from price mix of approximately 2%, partly offset by a return to volume growth with overall volumes up approximately 1%. Michael CasamentoEVP, Finance & CFO at Amcor00:12:36As expected, customer and consumer demand in the North America beverage business remained soft and variable through the quarter. While beverage volumes were down mid single digits, this marks an improvement on the Q1 of approximately 4 percentage points. Latin America volumes were down single digits versus last year, reflecting weaker customer demand in Argentina and Colombia, which was partly offset by growth in other countries including Brazil. The Specialty Containers business delivered strong growth in spirits, wine and beer with volumes down in Healthcare due to destocking and volumes in the closures business were higher than last year. From an earnings perspective, the business executed well in another quarter of growth and margin expansion reflecting benefits from an ongoing focus on cost and productivity measures. Michael CasamentoEVP, Finance & CFO at Amcor00:13:26Adjusted EBIT of CAD53 1,000,000 was up 10% on a comparable constant currency basis with EBIT margin increasing by 70 basis points to 7.3%. Finally, in late December, we completed the sale of our 50% interest in Vericap North America closures business, which we announced back in October. Proceeds of $122,000,000 were used to reduce debt demonstrating our commitment to disciplined capital allocation, which takes us to the cash flow and the balance sheet on slide 13. On a year to date basis, the business generated a net cash outflow of $38,000,000 which includes an inflow of more than $350,000,000 in cash flow in the 2nd quarter, approximately $80,000,000 better than last year's Q2, largely on the back of improvements in working capital. Stronger quarterly cash flow and receipt of proceeds from the Berry cap sale led to a reduction in net debt of approximately $375,000,000 compared with last quarter. Michael CasamentoEVP, Finance & CFO at Amcor00:14:22Leverage also improved sequentially coming in at 3.3 times, which is in line with the expectations we provided on our October call. We expect leverage to further reduce through the second half of the fiscal year and we remain confident in meeting our expectation to exit fiscal 2025 with leverage at 3 times or lower. Through the 1st 6 months of fiscal 2025, we returned approximately $365,000,000 in cash to shareholders through our quarterly dividend. This brings me to the outlook on slide 14. And as Pekay mentioned earlier, based on our solid first half performance and our confidence in the second half, we remain on track to deliver for the full year and we are again reaffirming our guidance. Michael CasamentoEVP, Finance & CFO at Amcor00:15:08For fiscal 2025, we continue to expect adjusted earnings to be in the range of $0.72 to $0.76 per share on a reported basis, representing comparable constant currency growth of 3% to 8%. We continue to expect to deliver strong growth in the underlying business for the year as earnings momentum continues to build. And as we've pointed out previously, it's important to remember that the guidance assumes an EPS headwind of up to 4% related to more normalized levels of incentive compensation based on our expectations for improved annual financial results. Excluding this incentive normalization, we expect growth from the underlying business in the mid single to low double digit range. We continue to assume overall volumes will increase in the low to mid single digit range for the year with trading performance through January aligned with this expectation. Michael CasamentoEVP, Finance & CFO at Amcor00:16:00We have updated our interest guidance to between $290,000,000 300,000,000 bringing the midpoint modestly lower to reflect the benefit in the second half related to the Berry Cat proceeds being used to reduce debt. And as a reminder, the overall impact of the Berry Cat sale on EPS for the year is relatively neutral, taking into account the loss of annualized EBIT of approximately $19,000,000 and the benefit of lower interest. Our effective tax rate range remains unchanged at 19% to 20%. In terms of phasing through fiscal 2025, we expect this will be aligned with historical average with the second half generating 55% to 58% of EPS based on our guidance range and the 4th quarter being the strongest of the year and typically 30% or more of full year EPS. And finally, we're affirming our expectations to generate strong adjusted free cash flow in the range of $900,000,000,000 to $1,000,000,000 for the year, supporting our confidence in exiting the year with leverage back at 3 times or lower as I noted earlier. Michael CasamentoEVP, Finance & CFO at Amcor00:17:02We are pleased with our continued execution across the underlying business and we are confident in our outlook for the year and we're excited about the additional opportunities we have to accelerate future growth through our combination with Berry. So with that, I'll hand back to PK. Peter KoniecznyChief Executive Officer at Amcor00:17:17Thanks, Michael. A Peter KoniecznyChief Executive Officer at Amcor00:17:19few closing remarks to summarize ahead of taking questions. We're executing well on the underlying business and are confident our merger with Berry is a winning combination for all stakeholders. The path to completion is clear with meaningful milestones already behind us. We remain highly focused on next steps to ensure we are setting the organization up for success and we remain on track and confident the transaction will close around the middle of calendar year 2020 5. Kate, we're ready to take questions. Operator00:18:11Your first question comes from the line of Anthony Pettinari with Citi. Please go ahead. Anthony PettinariAnalyst at Citigroup00:18:19Good morning. Peter KoniecznyChief Executive Officer at Amcor00:18:20Good morning, Anthony. Anthony PettinariAnalyst at Citigroup00:18:22Hey, you talked about potential divestitures to strengthen the business. And I'm just wondering, do you expect that those could be impactful at all to synergy targets or timeline? And then, is the divestiture opportunity, do you think it's larger than maybe you had expected late last year when you announced the deal? Or if there's any kind of color you can give us in terms of whether these are more likely Berry assets, Amcor assets or just any additional color you can give? Peter KoniecznyChief Executive Officer at Amcor00:18:54Yes. Thanks, Anthony. Look, I think you're talking about the portfolio pruning activities that I mentioned on a couple of calls earlier and also in the context of the berry combination. For me or for us, this is one of the additional levers that we can pull in order to orient the business towards a stronger, faster growing business organically and a business that is more attractive in terms of higher and better margin quality. Now with the the combination with Barry, we have sort of embarked on a work stream that essentially puts the whole portfolio on the table. Peter KoniecznyChief Executive Officer at Amcor00:19:40And we have started the conversations around that. So we're on it. And we're pretty much looking at everything. And as I said before, the criteria are there are multiple criteria that would we that we would apply to this analysis, but 2 of them are stronger intrinsic organic growth and then margin quality would be the 2 outstandings. It's a little early for us to say where we land and what we're going to do. Peter KoniecznyChief Executive Officer at Amcor00:20:07I think we need a little more time in order to come to a conclusion on it. But that is the key consideration here. I'm not sure it will have an impact on accelerating synergies and that's where you were coming from. I think it's really just about organic growth and making business more attractive terms of margin quality. Operator00:20:32Your next question comes from the line of Keith Chow with MST Marquis. Please go ahead. Keith ChauResearch Analyst at MST Financial00:20:39Hi, BK and Michael. Thanks for taking my question. So I just want to go back to a point around underlying demand. I think in the last quarter there's much discussion or even over the last year about volume growth returning as destocking ends. So it certainly seems as though that has happened. Keith ChauResearch Analyst at MST Financial00:21:01But in the last quarter you talked about underlying consumer demand still being fairly tepid and seemingly in the Q2 that hasn't changed too much. So I'm just wondering if you can update our views in that respect, whether there has been any restocking in the period? And to what extent do you believe price mix will improve in the flexibles division in the 3rd quarter and Q4? Is that going to be a positive outcome as that destocking in healthcare has ended? Thank you. Peter KoniecznyChief Executive Officer at Amcor00:21:34Yes, Keith, there's a couple of questions there. Let me try to sort them. So first of all, when we look at our volume expectations in the Q2, this fiscal year wasn't an exemption. We did not really expect consumer demand to strengthen a lot. We always talk about the consumer demand sort of in the range of being flat to slightly down. Peter KoniecznyChief Executive Officer at Amcor00:21:59And that is essentially what we've seen. Now when we look at scanner data and we look at other reporting from customers and we triangulate all that, I think we get to the conclusion of the consumer having modestly softened in the Q2 versus the first one. And that's just the way it is and we've seen that too. On the other hand, when I take a step back and look at our volume performance, I think it's important to calibrate against that environment. And we're actually pretty happy with the volume performance in the Q2. Peter KoniecznyChief Executive Officer at Amcor00:22:40Let me just highlight a few things here. We are up in the Q2 versus the Q1. And sequentially, we've almost seen a point of growth between Q1 and Q2. Flexibles is up 3%, Rigids is up overall 1%. When you look at the overall business, it was the 4th consecutive quarter of volume improvements or the 3rd consecutive quarter of volume growth that we've seen. Peter KoniecznyChief Executive Officer at Amcor00:23:06And then also to your question on pricemix or particularly mix, we are sitting in a spot where we believe that the healthcare destocking is pretty much behind us at this point. We've seen some abating destocking in the pharma subcategory in the last quarter in Q2. Maybe there is a bit of lingering destocking that sort of carries forward into Q3. But for all intents and purposes, I believe that we can talk about calendar 2025 as a year, which is going to be cleaner from a destocking perspective. And then the final point that I want to make is the or let me just say something else here on the point, the mix as healthcare is improving, I just want to make that point really clearly as healthcare is improving, we are going to see an improved mix exposure in the back half. Peter KoniecznyChief Executive Officer at Amcor00:24:01We're also pretty confident that healthcare will overall return back to growth. So that's on your mix question. And then coming back to the final point that I was going to make on the point of restocking. We never really felt that restocking would be a trend in the industry. What we have seen in the past was our customers across the different categories have built inventory in response to the supply chain shocks that we've seen in the past. Peter KoniecznyChief Executive Officer at Amcor00:24:31And after the supply chains sort of stabilized, there was an overall trend to fixing the inventory levels maybe even further because of the higher interest cost and the carrying value of inventory. Has driven it down to a new normal. What we see from here on are just seasonal inventory impacts, but nothing that sort of relates back to a structured destocking initiative. Operator00:25:04Your next question comes from the line of George Staphos with Bank of America. Please go ahead. George StaphosManaging Director at Bank of America Merrill Lynch00:25:10Thanks so much. Hi, everyone. Good morning and good afternoon. Question on the momentum within flexible packaging. Can you talk to the degree to which incentives and or FX might have impacted what otherwise would have been the EBIT conversion in Flexibles relative to the volume growth and whether EBIT itself in flexibles was in line with your forecast? George StaphosManaging Director at Bank of America Merrill Lynch00:25:40And as you're taking 2Q into 3Q, what kind of exit rates are you seeing on volume and conversion within flexibles and the categories you serve? Thank you. Peter KoniecznyChief Executive Officer at Amcor00:25:54Well, I can speak to the latter part of that question with regards to volumes and then maybe Michael sort of addresses some of the financial components. From a volume perspective, we're looking and that's across the business. We're looking at a first half that pretty much left us within our guidance range on volumes from lowtomidsingle digits. And that's therefore overall, it's pretty much exactly where we expect it to be. And as we exit the second quarter into the back half, I have no reasons to expect anything else for the back half. Peter KoniecznyChief Executive Officer at Amcor00:26:32So we're sitting here today and we're saying we're confirming the volume guidance of low to mid single digits for the full year. And that's across the categories that we see so flexibles and rigid. Michael CasamentoEVP, Finance & CFO at Amcor00:26:46Yes. And I think if we just talk about the profit performance of the business, I mean, we were pleased with where it ended in the quarter was in line with expectations. We continue to see good leverage through the P and L from that volume improvement to the EBIT improvement. And as we said earlier, we're still trailing a bit of negative mix particularly on the healthcare side of things. So that will certainly improve. Michael CasamentoEVP, Finance & CFO at Amcor00:27:15And I think from a cost standpoint as well, the business has continued to focus on that margin quality, but also the cost out. I guess one factor though is that clearly in the prior quarter in the prior year, we had a really strong cost out focus, particularly as we could see the impact of destocking pretty significantly earlier on in the quarter. And we took a lot of effort to really manage that cost and limit the impact of that volume. I mean, this year, clearly, we continue to focus on cost, but we are lapping a much more difficult comp. And that means we have put a little bit of labor back into the business, still getting that cost out, but have put labor back in just to ensure we don't miss any demand at all. Michael CasamentoEVP, Finance & CFO at Amcor00:28:03So we are pleased with where the business ended up. From an FX or incentive point, there's not really anything to speak to there. It wasn't a material impact. Operator00:28:20Your next question comes from the line of Daniel Kang with CLSA. Please go ahead. Daniel KangHead of Basic Industrials, Australian Equities Research at CLSA Limited00:28:27Good morning, everyone. So I understand that an integration planning event was recently held where both Amcor and Berry staff joined to form global work streams. Can you just shed some color on the event? I'm interested in whether the leadership team managed to walk away with greater confidence and perhaps greater granularity on the target synergies. Any comments that you can share, particularly on the key line items of procurement, G and A and operational be helpful? Daniel KangHead of Basic Industrials, Australian Equities Research at CLSA Limited00:29:00Thanks, P. K. Peter KoniecznyChief Executive Officer at Amcor00:29:02Thanks, Daniel. Look, first of all, it's all accurate what you said. We are according to the three priorities. We are also focusing on preparing the integration and we're expanding sort of our initiatives across a broader base of colleagues of 2 businesses in order to get ourselves ready to get out of the blocks fast once the acquisition closes. Now what we're currently doing is we're essentially organizing ourselves. Peter KoniecznyChief Executive Officer at Amcor00:29:36We're still it's still business as usual. We're still 2 different businesses. So we can't address the integration. We can start doing that. We can just plan it. Peter KoniecznyChief Executive Officer at Amcor00:29:45But one of the things that we do according to our playbook that we have within Amcor and Barry likewise has a lot of experience in integrating businesses is we're setting ourselves up with an integration management office and underneath that we're organizing ourselves with teams that will address the different work streams that will bring the 2 cultures together, but then also are focused on generating the synergies and so that we're able to deliver and outperform against that as the two companies come together. Now to the extent we have an opportunity to look further into the estimates that we've made at the time. We do actually gain confidence in the synergy bucket that we put into the market of the €650,000,000 most of which is cost related and breaks down on the cost side if I put the financial synergy opportunities aside between procurement, SG and A and then operations. So overall comment is we're gaining more confidence in the numbers that we put out there and that also applies for procurement, which is the biggest single item with €325,000,000 I just want to say just to dimensionalize the number which sounds comes across as a big number. Peter KoniecznyChief Executive Officer at Amcor00:31:07We have a spend between the 2 combined companies of about €13,000,000,000 If you look at the raw material side that's about €10,000,000 And if you sort of look at the procurement opportunities against that spend, we're sort of sitting around 3% of synergy capture, which we think is well aligned. So very confident in the synergies at this point in time. Operator00:31:32Your next question comes from the line of Ghansham Panjabi with Baird. Please go ahead. Matthew KruegerVice President & Senior Equity Research Analyst at Baird00:31:39Hi, good morning and afternoon everyone. Thanks for taking my question. This is actually Matt Kreger sitting in for Ghansham. Just wanted to follow-up on the raw materials front. Can you provide some added details and an update around what you're seeing in the raw material and other input cost basket across your business? Matthew KruegerVice President & Senior Equity Research Analyst at Baird00:31:58Maybe give us an updated outlook for the year? And any thoughts on if or how this latest round of tariffs impacts your cost base or maybe even how you're going to conduct your business? Any details there would be great. Thanks. Michael CasamentoEVP, Finance & CFO at Amcor00:32:15Yes, sure. I can help with that. It's Michael here. Look, from a raw material standpoint, the first half was really pretty benign. If you look at our numbers in the top line, in the revenue line, actually, the raw material number for the first half was flat. Michael CasamentoEVP, Finance & CFO at Amcor00:32:31So that tells you that the input costs overall were pretty flat for the first half. Q2 again was a similar trend to Q1. There was a little bit of pass through in Q2, but less than 1% in the top line and no impact in the earnings. And remember, we've got a broad base of goods across geographies, so they can move up and down at different rates. But generally, what we saw overall was the basket was pretty flat, perhaps down slightly. Michael CasamentoEVP, Finance & CFO at Amcor00:33:08And that included resins and liquids that were down in perhaps the low single digit range. And then there were some offsets with things like aluminum, which were up Michael CasamentoEVP, Finance & CFO at Amcor00:33:17what which were up in Michael CasamentoEVP, Finance & CFO at Amcor00:33:19the mid single digit range. As we then so pretty benign. If we look forward into Q3, it's about as far as we look out with any confidence. We'd say that it's probably a pretty similar view. Asia, Europe looking flat, perhaps in North America, some slight increases. Michael CasamentoEVP, Finance & CFO at Amcor00:33:41But overall, we'd expect the environment be relatively benign in Q3. And after that, we'll see what happens. From a tariff standpoint, I think our business is very regional. And in North America particularly, the level of imported goods is really very low and typically in specialty products that we can't get in this region. So from a tariff standpoint, that would be factored into the cost and then pass through. Michael CasamentoEVP, Finance & CFO at Amcor00:34:13So we don't really see a lot of impact on our business just because of the regional and local nature from any tariffs impacting the cost base. Peter KoniecznyChief Executive Officer at Amcor00:34:24And I may add to that. On the tariff side, 1st of all, everything that Michael said is very true. We're a very regional business. And if anything, we've become more regional given the experience from the past where long supply chains have essentially sort of created risk on the service levels to your customers. So we have even tried to shorten supply chains over the past. Peter KoniecznyChief Executive Officer at Amcor00:34:49And in terms of the ability to pass through tariffs, when you think about it, in some cases, we even have agreements with customers that would be based on indices that would allow us to pass on these additional costs. So I think we're in a spot where because we're regional, because we have some pass through opportunities, we feel we're not immune, but somewhat robust against the tariffs. Operator00:35:26Your next question comes from the line of Jacob Gokarnes with Jardens. Please go ahead. Jakob CakarnisDirector at Jarden Group Ltd00:35:32Hi, Peter. Hi, Michael. I just wanted to ask just about the trajectory in the Health business. So obviously some improvement there. It sounds like it's pharma that's still dragging on volumes. Jakob CakarnisDirector at Jarden Group Ltd00:35:44Just wondering as we move through the balance of the year, should the Berry merger complete? What's the exposure like to healthcare overall post merger? And do you think that the momentum that you're seeing gives you further confidence that you can drive that organic sales growth in the combined entity as you plan to please? Peter KoniecznyChief Executive Officer at Amcor00:36:06Yes. Well, thanks for that question because I'm a big healthcare fan. So I can take a step back and maybe help you sort of how we look at that. First of all, I believe that healthcare is a category that's a real gem in our portfolio. We've always said that from an anchor perspective and we're excited about the combination with Berry also because we can only strengthen that business. Peter KoniecznyChief Executive Officer at Amcor00:36:29Overall, when we combine the business, we're looking at about a $3,000,000,000 combined business in healthcare with really attractive exposures, which is also very complementary. On the Berry side, think about like multi component delivery devices, for example, inhalers that are being brought to market. And that is something that on the Amkra side, we have we do not have in our portfolio. So first of all, we believe that healthcare is a gem while it has been sort of challenged over the last couple of quarters because of pretty much significant destocking. You asked about the destocking. Peter KoniecznyChief Executive Officer at Amcor00:37:16We were essentially convinced that all of our categories have come to an end with destocking by the beginning of calendar 2024. The one that was left over really was healthcare because the destocking trend has started later and therefore lasted longer. As we then look at the 1st and the second quarter this fiscal year, we've seen definitely some destocking in the Q1 where the subcategory of medical had already returned to some growth, albeit small. But in pharma, we were pretty much challenged still with the destocking. We have seen in the Q2 medical further improve and strengthen. Peter KoniecznyChief Executive Officer at Amcor00:37:59On the pharma side, we've seen destocking abate. And again, we would now be in a spot where we'd say to keep things simple that destocking in healthcare is also over. Now realistically, there's probably going to be some lingering destocking that carries over in the Q3. I think I said that earlier today on a call on this call. But for the in the grand scheme of things, again, I think destocking is completely over. Peter KoniecznyChief Executive Officer at Amcor00:38:23With that said, healthcare will return back to growth. And we will get back to the historical growth rates 3%, 4% of healthcare over time. That will also take away the mix impact that we have in the translation to the bottom line. And overall, pretty excited with that going forward. Operator00:38:46Your next question comes from the line of Mike Roxanne with Chirrus Securities. Please go ahead. Michael RoxlandMD - Equity Research at Truist Securities00:38:53Thank you, P. K, Michael, Tracy, Dana for taking my questions. Michael RoxlandMD - Equity Research at Truist Securities00:38:59As you're proceeding through the Michael RoxlandMD - Equity Research at Truist Securities00:39:00due diligence process with Berry, is there anything that stands out that you weren't expecting upside, downside? My sense is that obviously some of the synergies do have some upside given your comments, PK, earlier. Then secondly, just given that growth, overall volume growth is slowly improving in the base Amicore business, is there anything you're doing maybe from a cost vantage point to help drive better profitability? Thanks. Peter KoniecznyChief Executive Officer at Amcor00:39:27Yes, Mike. So just got to think about the first question. There were 2 questions here. Can you guys help me with the first one? Tracey WhiteheadHead, IR at Amcor00:39:38Anything that stands out in the due diligence? Peter KoniecznyChief Executive Officer at Amcor00:39:40Yes. Thank you. So due diligence. Look, I would say there are no surprises on our side as we moved from announcing the deal a couple of months ago to where we're at today. But you got to remember, it's business as usual at this point in time, right? Peter KoniecznyChief Executive Officer at Amcor00:40:00So the data that we have available to look at is pretty much to a large extent really just the data that we had and that will significantly change only as we come to closing, which we expect to be in the middle of this calendar year, which has not changed versus what we've done before. So that's the answer to the first part of your question, is there anything positive or negative? We're pretty much in a spot where everything is as expected. And from a synergy perspective, you also mentioned that. And I think, yes, we are becoming more confident in the synergies. Peter KoniecznyChief Executive Officer at Amcor00:40:43So that is all positive. Now the second part of the question, I should have yes, Michael, do you want to take that? Michael CasamentoEVP, Finance & CFO at Amcor00:40:51Yes, I'll take that one, Pico. Sure. No, thanks for that part of the question, Mike. Yes, look on the cost side, we continue to focus on driving efficiency in our operations and our plants, managing the labor pool and flexing that to the volume as needed. We continue to look at the shift patterns and managing over time. Michael CasamentoEVP, Finance & CFO at Amcor00:41:13And we've also still got some residual benefits to come through from the restructuring programs that we had in place that we called out a couple of years ago in relation to offsetting some of those disposed earnings from Russia. So in the first half, we probably picked up about $7,000,000 benefit there and we've probably got another $7,000,000 or to come in the second half. So overall, it's a really strong cost focus and both operationally and still some benefits to come from the restructuring. So that's all factored into our guidance that we reaffirmed for the full year. Operator00:41:48Your next question comes from the line of John Pirtle with Macquarie. Please go ahead. John PurtellDivisional Director, Senior Analyst at Macquarie Group00:41:54Good day, Peter and Michael. Hope you're well. Look, just coming back to Berry, obviously, and thanks for the comments there on healthcare, Peter. But obviously, Berry globalizes your rigid business. John PurtellDivisional Director, Senior Analyst at Macquarie Group00:42:09I mean, what do you see as the sort of John PurtellDivisional Director, Senior Analyst at Macquarie Group00:42:11key benefits of that? And if you can also please touch on the growth outlook for closures and dispensing systems and what that potentially gives you? Thank you. Peter KoniecznyChief Executive Officer at Amcor00:42:23Thanks, John. So on the rigid business, you said it globalizes our rigid business. Let me be a little more specific about that and pull that apart, because I think it's really important. First of all, in terms of Quantum, our Rigids business, we summarize under the roof of Rigid Packaging, which is about a $3,000,000,000 business. And the Berry business has a containers and closures business, which is about a $7,000,000,000 business. Peter KoniecznyChief Executive Officer at Amcor00:42:57Hence, the combination will get us to a really scaled player and multi regions and that's different from what we have today. Now the key difference though is that we play only partly in the incomparable call it sub segments. When I dissect our rigid packaging business, it I would split it generally between the North American beverage business, which we discuss quite often because it's a scale business. It's in the beverage side. It sits in North America and it serves categories like isotonic ready to drink tea where we have some underlying challenges right now because it's a more discretionary category as we've discussed many times. Peter KoniecznyChief Executive Officer at Amcor00:43:45That's a scale volume driven business where we're very well positioned in North America on the Amcor side. The other part of that business is around specialty containers. That's a different business. It's also a scale business, but not as big as the North American beverage business, which serves a number of different categories and makes containers for those categories across the board. Now, the berry side of the containers business is much more comparable to the specialty containers business of Amcor. Peter KoniecznyChief Executive Officer at Amcor00:44:18That's where the complementarity comes in. In fact, berry doesn't do anything on the North American beverage business. They don't have exposure to that type of a segment. So we believe that is very positive for us because we were very interested in scaling up the specialty containers business as we call it which is very much aligned the berry business. And again on the berry side we have really good high value products. Peter KoniecznyChief Executive Officer at Amcor00:44:49When you think about it, it is the containers business of berry that actually brings along the healthcare exposure. And I talked about that earlier. Here we see the multi component more complex delivery systems on the healthcare side and there is other parts of the business that we likewise are attracted to. When you then go to the closure side of Berry, which is an addition to our business, particularly after we've divested our joint venture stake in the BerryCap joint venture, then you will find a nice exposure to dispensing systems and pumps that we likewise are very attracted to. So it is very complementary and it's not in the North American beverage space. Peter KoniecznyChief Executive Officer at Amcor00:45:41And therefore, we are pretty excited about the combination. Now you also asked us for our growth assumptions in the case of closures and dispensing systems. I think it's a little too early for me to give you like a concrete answer to that, that you can hold me to as we go forward. So I'll ask for a little more time for me to go back to that and confirm that on a later call. Operator00:46:16Your next question comes from the line of Keith Chow with MST Marquis. Please go ahead. Keith ChauResearch Analyst at MST Financial00:46:22Thanks so much for taking my follow-up question. Michael, just one for you. The last result, I think you guided to first half, second half split of 45, 55, which I think based on what's been achieved in the first half, that split implies the bottom of the guidance range. So I'm sorry to ask you a mathematical question, but the top end does imply sorry, the midpoint does imply a slightly greater skew to the second half. So given the top half now represents something more like $42,000,000 to $58,000,000 How are you thinking about that split going into the full year given what's happened in the first half or what's been achieved in the first half? Keith ChauResearch Analyst at MST Financial00:46:58Thank you. Michael CasamentoEVP, Finance & CFO at Amcor00:47:00Yes. Okay. Look, I think as I said in my comments, I mean, we are basing the phasing on the historical average is what we're expecting. And that's a range, right? I think when I talked Q1 last time around, it was approximately 25% to 55%, but it can vary on the margin. Michael CasamentoEVP, Finance & CFO at Amcor00:47:19I think, you know, as we've exited the first half, you know, it was right in line with our expectations. You know, volumes in that low single digit range, the margins were, you know, continue to expand and we saw the EPS, you know, growing at 5 percent. As we've kind of exited that, we looked into January and then looked at the outlook, we feel really confident in the second half, which is why we've reaffirmed our guidance today. And that as PK said, that implies the second half low single digit to mid single digit volume growth. That's going to be a key driver obviously of the outcome of the year. Michael CasamentoEVP, Finance & CFO at Amcor00:47:58And I think in terms of the range we've given you, the importance of the range, the volume particularly as we get into the higher seasonal seasonality of the business, particularly in Q4. I mean, we don't need a lot of volume improvement to really see strong leverage through the P and L, particularly in Q4 where the cost base is well covered off. That's the biggest quarter of the year, typically above 30% of earnings. And the other thing to take into account as well is clearly we're expecting the mix improvement in the second half as a result of the Healthcare business returning to growth and lapping that peak period of destocking last year. So from here, we sit we've reaffirmed guidance. Michael CasamentoEVP, Finance & CFO at Amcor00:48:43We feel pretty confident in that. And we'll update you in May as we work our way through the year. Operator00:48:50Ladies and gentlemen, this concludes our question and answer session. I will now turn the call back to Peter for closing remarks. Peter KoniecznyChief Executive Officer at Amcor00:48:58Yes. Thank you, Kate. Look, given the overall environment, we feel pretty confident and we feel pretty good about the quarter that we've delivered and I hope that came across. So again, we believe it's been a good quarter. The volume growth improved pretty confident in the second half and we've reaffirmed guidance on the back of that. Peter KoniecznyChief Executive Officer at Amcor00:49:22Thank you very much for your questions and your time. And I look forward or we look forward to having the opportunity to meet some of you at the upcoming conferences. Thank you very much. Operator00:49:34Ladies and gentlemen, that concludes today's call. Thank you and have a great day.Read moreParticipantsExecutivesTracey WhiteheadHead, IRPeter KoniecznyChief Executive OfficerMichael CasamentoEVP, Finance & CFOAnalystsAnthony PettinariAnalyst at CitigroupKeith ChauResearch Analyst at MST FinancialGeorge StaphosManaging Director at Bank of America Merrill LynchDaniel KangHead of Basic Industrials, Australian Equities Research at CLSA LimitedMatthew KruegerVice President & Senior Equity Research Analyst at BairdJakob CakarnisDirector at Jarden Group LtdMichael RoxlandMD - Equity Research at Truist SecuritiesJohn PurtellDivisional Director, Senior Analyst at Macquarie GroupPowered by Conference Call Audio Live Call not available Earnings Conference CallAmcor Q2 202500:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipants Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) Amcor Earnings HeadlinesElliott Wave Technical Forecast : Amcor Plc April 24 at 12:46 PM | talkmarkets.comAmcor (NYSE:AMCR) Given New $11.00 Price Target at Truist FinancialApril 23 at 3:37 AM | americanbankingnews.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)Amcor (NYSE:AMCR) Coverage Initiated at Raymond JamesApril 23 at 3:37 AM | americanbankingnews.comAmcor initiated with a Market Perform at Raymond JamesApril 22 at 11:40 PM | markets.businessinsider.comAmcor Files SEC Document on Berry Global GroupApril 16, 2025 | tipranks.comSee More Amcor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amcor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amcor and other key companies, straight to your email. Email Address About AmcorAmcor (NYSE:AMCR) develops, produces, and sells packaging products in Europe, North America, Latin America, Africa, and the Asia Pacific regions. The company operates through two segments, Flexibles and Rigid Packaging. The Flexibles segment provides flexible and film packaging products in the food and beverage, medical and pharmaceutical, fresh produce, snack food, personal care, and other industries. The Rigid Packaging segment offers rigid containers for various beverage and food products, including carbonated soft drinks, water, juices, sports drinks, milk-based beverages, spirits and beer, sauces, dressings, spreads, and personal care items; and plastic caps for various applications. The company sells its products through its direct sales force. Amcor plc was incorporated in 2018 and is headquartered in Zurich, Switzerland.View Amcor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Operator00:00:00Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amcor Half Year Results 2025. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Operator00:00:30Thank you. I would now like to turn the call over to Tracey Whitehead, Head of Investor Relations. Please go ahead. Tracey WhiteheadHead, IR at Amcor00:00:37Thank you, Kate, and thank you everyone for joining Amcor's fiscal 2025 2nd quarter earnings call. Joining today is Peter Konichne, Chief Executive Officer and Michael Casamento, Chief Financial Officer. Before I hand over, let me note a few items. On our website, dotcom, under the Investors section, you'll find today's press release and presentation, which we'll discuss on this call. Please be aware that we will also discuss non GAAP financial measures and related reconciliations can be found in that press release and the presentation. Tracey WhiteheadHead, IR at Amcor00:01:16Remarks will also include forward looking statements that are based on management's current views and assumptions. The second and third slides in today's presentation list several factors that could cause future results to be different than current estimates. Reference can be made to Amcor's SEC filings, including our statements on Form 10 ks and 10 Q for further details. Please note that during the question and answer session, we request that you limit yourself to a single question and then rejoin the queue if you have any additional questions or follow ups. With that, over to you, P. Tracey WhiteheadHead, IR at Amcor00:01:51K. Peter KoniecznyChief Executive Officer at Amcor00:01:52Thank you, Tracy, and thank you to all who have joined us for today's call. Omcor had a very active second quarter and we're progressing well on 3 clear priorities. 1, deliver on the base business 2, complete the work required to close the announced merger with Berry Global and 3, make sure we are well prepared for a fast start and integration. With the base business, we start as always with safety on Slide 4. I'm incredibly proud of the commitment our teams demonstrate to safety every day. Peter KoniecznyChief Executive Officer at Amcor00:02:24The safety and well-being of our people will always be our top priority and we're constantly looking for opportunities to improve. In fiscal 2025 to date, we have continued to deliver outstanding results. We achieved an industry leading total recordable incident rate of 0.30 and 79% of our sites remained injury free for more than a year. Our key messages for today are on Slide 5. Q2 results were in line with expectations we set in October as we continued to execute and deliver across key financial metrics. Peter KoniecznyChief Executive Officer at Amcor00:02:59We are pleased to report our 4th consecutive quarter of sequential volume improvement and a return to sales growth albeit marginal. Margins also continued to improve helping drive a 5% increase in both adjusted EBIT and EPS on a comparable basis. The solid performance along with our confidence in the second half leaves us on track to deliver against our full year guidance which we are reaffirming again today. And finally, as we continue to execute well on the underlying business, we're also highly focused on the unique opportunity we have to accelerate growth and enhance margin enhance earnings and cash generation through the previously announced combination with Berry. Turning to slide 6. Peter KoniecznyChief Executive Officer at Amcor00:03:43On our Q1 earnings call in October, I outlined my strategy for Amgore to deliver consistent sustainable organic growth in the low to mid single digit range through an unwavering focus on our customers on sustainability and on our portfolio mix. I also shared my future vision for Amcor to become the global packaging partner of choice. The merger with Berry is directly aligned with this strategy and moves us further towards our vision. Slide 7 highlights the compelling rationale behind this combination. 1 of the most powerful and transformational long term benefits of this merger is the opportunity to drive stronger, more consistent and sustainable volume driven organic growth and to further improve margins. Peter KoniecznyChief Executive Officer at Amcor00:04:28There are a number of growth unlocks that will become available with 2 of the most significant shown on this slide. First, the combined company will be a better business with a broader primary packaging portfolio at scale across consumer goods and healthcare end markets. In the context of a stronger larger scale company, AMKRE will be uniquely positioned to further refine and prune our portfolio mix to focus even more on attractive higher value faster growing end markets. This journey is already underway with Berry's recent divestitures of its HHNF and Tapes businesses which have significantly enhanced their product mix while reducing cyclicality. As a result of further pruning, we will increase average growth rates, margins and cash generation across the remaining portfolio. Peter KoniecznyChief Executive Officer at Amcor00:05:182nd, this combination creates exceptional capability in material science and innovation. We will drive growth for innovation and more sustainable packaging solutions by effectively and efficiently leveraging our combined resources bringing together more than 1500 R and D professionals and annual R and D investment of $180,000,000 will allow us to optimize and redirect R and D spend providing capacity to focus on solving the most complex functionality and sustainability challenges faced by our customers and consumers. Accelerated growth combined with significant synergies means this combination will drive compelling near and long term value for all shareholders. Moving to Slide 8. You've seen this slide before, but let me recap a few of the drivers behind the significant and sustainable financial value we're creating. Peter KoniecznyChief Executive Officer at Amcor00:06:10We continue to pressure test our assumptions and are confident in the $650,000,000 in total cost growth and financial synergies we've identified and will deliver. We expect to realize 40 percent or $260,000,000 of total synergies in the 1st year and the full run rate in year 3 with an additional $280,000,000 of one time cash benefits from working capital improvements, which will fund cash costs to achieve synergies. Including synergies, this combination is expected to deliver significant cash EPS accretion of over 35% and annual cash flow in excess of $3,000,000,000 This will allow us to maintain a strong investment grade balance sheet and deploy additional cash to invest in organic growth and M and A. We expect to increase long term EPS growth and take the outcomes under our value shareholder value creation model to a new and higher level. Turning to slide 9 and an update on the steps we have taken towards closing. Peter KoniecznyChief Executive Officer at Amcor00:07:13We are moving very quickly from a process perspective to complete the work required to bring the merger to close. On January 23, we filed the definitive joint proxy statement prospectus with the SEC and shareholder meetings are scheduled to take place on February 25. Initial materials required to secure regulatory approvals across nearly all required jurisdictions have been submitted and the first approvals have been received. The composition of the Board of Directors has been finalized and our path to completion is well advanced. From an integration preparedness perspective, we're also well positioned. Peter KoniecznyChief Executive Officer at Amcor00:07:50We are focused on building our teams, filling key roles, ensuring we will make a fast start upon close with clearly defined plans for the 1st 100 days in line with our proven integration playbook. We have a strong track record of successfully executing on large transactions and our teams have significant experience in integrating sizable businesses. Moving to slide 10 for a summary of our financial results. As noted earlier, delivering on the base business is a top priority and we continue to execute well with 2nd quarter results in line with the expectations we outlined in October. Our differentiated value proposition resonates with customers supporting a return to overall sales growth in Q2 as net sales of $3,200,000,000 were slightly ahead of last year. Peter KoniecznyChief Executive Officer at Amcor00:08:38Overall volumes grew by 2.3% improving on the Q1 and offsetting an unfavorable impact of price mix. This was the 4th consecutive quarter of sequential improvement in volumes. As expected, destocking continued in healthcare and demand remained soft in the North American beverage business, impacting mix and unfavorably impacting overall volumes by more than 1%. Across the balance of the business, overall volume growth was consistent with the Q1 up approximately 4%. Improving volume trends and continued proactive cost and productivity actions more than offset unfavorable price mix headwinds leading to another quarter of solid earnings growth. Peter KoniecznyChief Executive Officer at Amcor00:09:18Adjusted EBIT increased by 5% compared with last year and adjusted adjusted EBIT margin expanded by over year over year by 40 basis points. Adjusted earnings per share of $0.1601 also grew by 5% on a comparable basis and cash generation was above the prior year positioning us to reaffirm our fiscal year guidance. I'll now turn the call over to Michael to cover the results and outlook in more detail. Michael CasamentoEVP, Finance & CFO at Amcor00:09:44Thanks, Pekay, and hello, everyone. Beginning with Flexibles segment on Slide 11 and focusing on our fiscal Q2 performance. Q2 volumes were up 3% compared with last year, reflecting ongoing solid growth across all key geographies and a number of important end markets. Net sales also returned to growth increasing by 1% on a comparable constant currency basis and higher volumes more than offset unfavorable price mix of approximately 2% primarily related to lower healthcare volumes. As expected and discussed in prior earnings calls, we continued to see destocking in the healthcare in North America and Europe Pharmaceuticals, which resulted in a headwind of approximately 1% to overall segment volumes. Michael CasamentoEVP, Finance & CFO at Amcor00:10:33Compared to the fiscal Q1, destocking abated and the related price mix headwind improved. And exiting the Q2, we believe Healthcare destocking is now largely behind us. Across the balance of our flexibles portfolio, volumes were up 4% reflecting solid demand across regions and in many product categories. In North America and Europe, 2nd quarter demand remained solid with volumes increasing mid single digits in both regions despite the negative impact of Healthcare destocking. Top line growth was strong across the Asian region reflecting price mix benefits and mid single digit volume growth supported by strong demand in China and across Southeast Asia. Michael CasamentoEVP, Finance & CFO at Amcor00:11:18In Latin America, volumes were broadly in line with last year's Q2 with good growth in Colombia and Peru offset by demand in Argentina. From a product category standpoint, ready meals and premium coffee showed strong growth and dairy, meat, liquids and pet care were up low to mid single digits. In healthcare, medical returned to growth. However, pharma volumes continued to be down low double digits compared with last year as a result of destocking. And as I mentioned earlier is now largely behind us. Michael CasamentoEVP, Finance & CFO at Amcor00:11:51Good earnings leverage continued and adjusted EBIT for the quarter of $322,000,000 grew by 4 percent on a comparable constant currency basis. Higher volumes combined with strong cost performance and the benefits from restructuring led to another quarter of margin expansion with adjusted EBIT margins up 20 basis points to 12.8%. Turning to Rigid Packaging on slide 12. The Rigid business continues to advance its performance and the trajectory of overall segment volumes improved for the 4th consecutive quarter. Net sales were approximately 1% lower than last year reflecting an unfavorable impact from price mix of approximately 2%, partly offset by a return to volume growth with overall volumes up approximately 1%. Michael CasamentoEVP, Finance & CFO at Amcor00:12:36As expected, customer and consumer demand in the North America beverage business remained soft and variable through the quarter. While beverage volumes were down mid single digits, this marks an improvement on the Q1 of approximately 4 percentage points. Latin America volumes were down single digits versus last year, reflecting weaker customer demand in Argentina and Colombia, which was partly offset by growth in other countries including Brazil. The Specialty Containers business delivered strong growth in spirits, wine and beer with volumes down in Healthcare due to destocking and volumes in the closures business were higher than last year. From an earnings perspective, the business executed well in another quarter of growth and margin expansion reflecting benefits from an ongoing focus on cost and productivity measures. Michael CasamentoEVP, Finance & CFO at Amcor00:13:26Adjusted EBIT of CAD53 1,000,000 was up 10% on a comparable constant currency basis with EBIT margin increasing by 70 basis points to 7.3%. Finally, in late December, we completed the sale of our 50% interest in Vericap North America closures business, which we announced back in October. Proceeds of $122,000,000 were used to reduce debt demonstrating our commitment to disciplined capital allocation, which takes us to the cash flow and the balance sheet on slide 13. On a year to date basis, the business generated a net cash outflow of $38,000,000 which includes an inflow of more than $350,000,000 in cash flow in the 2nd quarter, approximately $80,000,000 better than last year's Q2, largely on the back of improvements in working capital. Stronger quarterly cash flow and receipt of proceeds from the Berry cap sale led to a reduction in net debt of approximately $375,000,000 compared with last quarter. Michael CasamentoEVP, Finance & CFO at Amcor00:14:22Leverage also improved sequentially coming in at 3.3 times, which is in line with the expectations we provided on our October call. We expect leverage to further reduce through the second half of the fiscal year and we remain confident in meeting our expectation to exit fiscal 2025 with leverage at 3 times or lower. Through the 1st 6 months of fiscal 2025, we returned approximately $365,000,000 in cash to shareholders through our quarterly dividend. This brings me to the outlook on slide 14. And as Pekay mentioned earlier, based on our solid first half performance and our confidence in the second half, we remain on track to deliver for the full year and we are again reaffirming our guidance. Michael CasamentoEVP, Finance & CFO at Amcor00:15:08For fiscal 2025, we continue to expect adjusted earnings to be in the range of $0.72 to $0.76 per share on a reported basis, representing comparable constant currency growth of 3% to 8%. We continue to expect to deliver strong growth in the underlying business for the year as earnings momentum continues to build. And as we've pointed out previously, it's important to remember that the guidance assumes an EPS headwind of up to 4% related to more normalized levels of incentive compensation based on our expectations for improved annual financial results. Excluding this incentive normalization, we expect growth from the underlying business in the mid single to low double digit range. We continue to assume overall volumes will increase in the low to mid single digit range for the year with trading performance through January aligned with this expectation. Michael CasamentoEVP, Finance & CFO at Amcor00:16:00We have updated our interest guidance to between $290,000,000 300,000,000 bringing the midpoint modestly lower to reflect the benefit in the second half related to the Berry Cat proceeds being used to reduce debt. And as a reminder, the overall impact of the Berry Cat sale on EPS for the year is relatively neutral, taking into account the loss of annualized EBIT of approximately $19,000,000 and the benefit of lower interest. Our effective tax rate range remains unchanged at 19% to 20%. In terms of phasing through fiscal 2025, we expect this will be aligned with historical average with the second half generating 55% to 58% of EPS based on our guidance range and the 4th quarter being the strongest of the year and typically 30% or more of full year EPS. And finally, we're affirming our expectations to generate strong adjusted free cash flow in the range of $900,000,000,000 to $1,000,000,000 for the year, supporting our confidence in exiting the year with leverage back at 3 times or lower as I noted earlier. Michael CasamentoEVP, Finance & CFO at Amcor00:17:02We are pleased with our continued execution across the underlying business and we are confident in our outlook for the year and we're excited about the additional opportunities we have to accelerate future growth through our combination with Berry. So with that, I'll hand back to PK. Peter KoniecznyChief Executive Officer at Amcor00:17:17Thanks, Michael. A Peter KoniecznyChief Executive Officer at Amcor00:17:19few closing remarks to summarize ahead of taking questions. We're executing well on the underlying business and are confident our merger with Berry is a winning combination for all stakeholders. The path to completion is clear with meaningful milestones already behind us. We remain highly focused on next steps to ensure we are setting the organization up for success and we remain on track and confident the transaction will close around the middle of calendar year 2020 5. Kate, we're ready to take questions. Operator00:18:11Your first question comes from the line of Anthony Pettinari with Citi. Please go ahead. Anthony PettinariAnalyst at Citigroup00:18:19Good morning. Peter KoniecznyChief Executive Officer at Amcor00:18:20Good morning, Anthony. Anthony PettinariAnalyst at Citigroup00:18:22Hey, you talked about potential divestitures to strengthen the business. And I'm just wondering, do you expect that those could be impactful at all to synergy targets or timeline? And then, is the divestiture opportunity, do you think it's larger than maybe you had expected late last year when you announced the deal? Or if there's any kind of color you can give us in terms of whether these are more likely Berry assets, Amcor assets or just any additional color you can give? Peter KoniecznyChief Executive Officer at Amcor00:18:54Yes. Thanks, Anthony. Look, I think you're talking about the portfolio pruning activities that I mentioned on a couple of calls earlier and also in the context of the berry combination. For me or for us, this is one of the additional levers that we can pull in order to orient the business towards a stronger, faster growing business organically and a business that is more attractive in terms of higher and better margin quality. Now with the the combination with Barry, we have sort of embarked on a work stream that essentially puts the whole portfolio on the table. Peter KoniecznyChief Executive Officer at Amcor00:19:40And we have started the conversations around that. So we're on it. And we're pretty much looking at everything. And as I said before, the criteria are there are multiple criteria that would we that we would apply to this analysis, but 2 of them are stronger intrinsic organic growth and then margin quality would be the 2 outstandings. It's a little early for us to say where we land and what we're going to do. Peter KoniecznyChief Executive Officer at Amcor00:20:07I think we need a little more time in order to come to a conclusion on it. But that is the key consideration here. I'm not sure it will have an impact on accelerating synergies and that's where you were coming from. I think it's really just about organic growth and making business more attractive terms of margin quality. Operator00:20:32Your next question comes from the line of Keith Chow with MST Marquis. Please go ahead. Keith ChauResearch Analyst at MST Financial00:20:39Hi, BK and Michael. Thanks for taking my question. So I just want to go back to a point around underlying demand. I think in the last quarter there's much discussion or even over the last year about volume growth returning as destocking ends. So it certainly seems as though that has happened. Keith ChauResearch Analyst at MST Financial00:21:01But in the last quarter you talked about underlying consumer demand still being fairly tepid and seemingly in the Q2 that hasn't changed too much. So I'm just wondering if you can update our views in that respect, whether there has been any restocking in the period? And to what extent do you believe price mix will improve in the flexibles division in the 3rd quarter and Q4? Is that going to be a positive outcome as that destocking in healthcare has ended? Thank you. Peter KoniecznyChief Executive Officer at Amcor00:21:34Yes, Keith, there's a couple of questions there. Let me try to sort them. So first of all, when we look at our volume expectations in the Q2, this fiscal year wasn't an exemption. We did not really expect consumer demand to strengthen a lot. We always talk about the consumer demand sort of in the range of being flat to slightly down. Peter KoniecznyChief Executive Officer at Amcor00:21:59And that is essentially what we've seen. Now when we look at scanner data and we look at other reporting from customers and we triangulate all that, I think we get to the conclusion of the consumer having modestly softened in the Q2 versus the first one. And that's just the way it is and we've seen that too. On the other hand, when I take a step back and look at our volume performance, I think it's important to calibrate against that environment. And we're actually pretty happy with the volume performance in the Q2. Peter KoniecznyChief Executive Officer at Amcor00:22:40Let me just highlight a few things here. We are up in the Q2 versus the Q1. And sequentially, we've almost seen a point of growth between Q1 and Q2. Flexibles is up 3%, Rigids is up overall 1%. When you look at the overall business, it was the 4th consecutive quarter of volume improvements or the 3rd consecutive quarter of volume growth that we've seen. Peter KoniecznyChief Executive Officer at Amcor00:23:06And then also to your question on pricemix or particularly mix, we are sitting in a spot where we believe that the healthcare destocking is pretty much behind us at this point. We've seen some abating destocking in the pharma subcategory in the last quarter in Q2. Maybe there is a bit of lingering destocking that sort of carries forward into Q3. But for all intents and purposes, I believe that we can talk about calendar 2025 as a year, which is going to be cleaner from a destocking perspective. And then the final point that I want to make is the or let me just say something else here on the point, the mix as healthcare is improving, I just want to make that point really clearly as healthcare is improving, we are going to see an improved mix exposure in the back half. Peter KoniecznyChief Executive Officer at Amcor00:24:01We're also pretty confident that healthcare will overall return back to growth. So that's on your mix question. And then coming back to the final point that I was going to make on the point of restocking. We never really felt that restocking would be a trend in the industry. What we have seen in the past was our customers across the different categories have built inventory in response to the supply chain shocks that we've seen in the past. Peter KoniecznyChief Executive Officer at Amcor00:24:31And after the supply chains sort of stabilized, there was an overall trend to fixing the inventory levels maybe even further because of the higher interest cost and the carrying value of inventory. Has driven it down to a new normal. What we see from here on are just seasonal inventory impacts, but nothing that sort of relates back to a structured destocking initiative. Operator00:25:04Your next question comes from the line of George Staphos with Bank of America. Please go ahead. George StaphosManaging Director at Bank of America Merrill Lynch00:25:10Thanks so much. Hi, everyone. Good morning and good afternoon. Question on the momentum within flexible packaging. Can you talk to the degree to which incentives and or FX might have impacted what otherwise would have been the EBIT conversion in Flexibles relative to the volume growth and whether EBIT itself in flexibles was in line with your forecast? George StaphosManaging Director at Bank of America Merrill Lynch00:25:40And as you're taking 2Q into 3Q, what kind of exit rates are you seeing on volume and conversion within flexibles and the categories you serve? Thank you. Peter KoniecznyChief Executive Officer at Amcor00:25:54Well, I can speak to the latter part of that question with regards to volumes and then maybe Michael sort of addresses some of the financial components. From a volume perspective, we're looking and that's across the business. We're looking at a first half that pretty much left us within our guidance range on volumes from lowtomidsingle digits. And that's therefore overall, it's pretty much exactly where we expect it to be. And as we exit the second quarter into the back half, I have no reasons to expect anything else for the back half. Peter KoniecznyChief Executive Officer at Amcor00:26:32So we're sitting here today and we're saying we're confirming the volume guidance of low to mid single digits for the full year. And that's across the categories that we see so flexibles and rigid. Michael CasamentoEVP, Finance & CFO at Amcor00:26:46Yes. And I think if we just talk about the profit performance of the business, I mean, we were pleased with where it ended in the quarter was in line with expectations. We continue to see good leverage through the P and L from that volume improvement to the EBIT improvement. And as we said earlier, we're still trailing a bit of negative mix particularly on the healthcare side of things. So that will certainly improve. Michael CasamentoEVP, Finance & CFO at Amcor00:27:15And I think from a cost standpoint as well, the business has continued to focus on that margin quality, but also the cost out. I guess one factor though is that clearly in the prior quarter in the prior year, we had a really strong cost out focus, particularly as we could see the impact of destocking pretty significantly earlier on in the quarter. And we took a lot of effort to really manage that cost and limit the impact of that volume. I mean, this year, clearly, we continue to focus on cost, but we are lapping a much more difficult comp. And that means we have put a little bit of labor back into the business, still getting that cost out, but have put labor back in just to ensure we don't miss any demand at all. Michael CasamentoEVP, Finance & CFO at Amcor00:28:03So we are pleased with where the business ended up. From an FX or incentive point, there's not really anything to speak to there. It wasn't a material impact. Operator00:28:20Your next question comes from the line of Daniel Kang with CLSA. Please go ahead. Daniel KangHead of Basic Industrials, Australian Equities Research at CLSA Limited00:28:27Good morning, everyone. So I understand that an integration planning event was recently held where both Amcor and Berry staff joined to form global work streams. Can you just shed some color on the event? I'm interested in whether the leadership team managed to walk away with greater confidence and perhaps greater granularity on the target synergies. Any comments that you can share, particularly on the key line items of procurement, G and A and operational be helpful? Daniel KangHead of Basic Industrials, Australian Equities Research at CLSA Limited00:29:00Thanks, P. K. Peter KoniecznyChief Executive Officer at Amcor00:29:02Thanks, Daniel. Look, first of all, it's all accurate what you said. We are according to the three priorities. We are also focusing on preparing the integration and we're expanding sort of our initiatives across a broader base of colleagues of 2 businesses in order to get ourselves ready to get out of the blocks fast once the acquisition closes. Now what we're currently doing is we're essentially organizing ourselves. Peter KoniecznyChief Executive Officer at Amcor00:29:36We're still it's still business as usual. We're still 2 different businesses. So we can't address the integration. We can start doing that. We can just plan it. Peter KoniecznyChief Executive Officer at Amcor00:29:45But one of the things that we do according to our playbook that we have within Amcor and Barry likewise has a lot of experience in integrating businesses is we're setting ourselves up with an integration management office and underneath that we're organizing ourselves with teams that will address the different work streams that will bring the 2 cultures together, but then also are focused on generating the synergies and so that we're able to deliver and outperform against that as the two companies come together. Now to the extent we have an opportunity to look further into the estimates that we've made at the time. We do actually gain confidence in the synergy bucket that we put into the market of the €650,000,000 most of which is cost related and breaks down on the cost side if I put the financial synergy opportunities aside between procurement, SG and A and then operations. So overall comment is we're gaining more confidence in the numbers that we put out there and that also applies for procurement, which is the biggest single item with €325,000,000 I just want to say just to dimensionalize the number which sounds comes across as a big number. Peter KoniecznyChief Executive Officer at Amcor00:31:07We have a spend between the 2 combined companies of about €13,000,000,000 If you look at the raw material side that's about €10,000,000 And if you sort of look at the procurement opportunities against that spend, we're sort of sitting around 3% of synergy capture, which we think is well aligned. So very confident in the synergies at this point in time. Operator00:31:32Your next question comes from the line of Ghansham Panjabi with Baird. Please go ahead. Matthew KruegerVice President & Senior Equity Research Analyst at Baird00:31:39Hi, good morning and afternoon everyone. Thanks for taking my question. This is actually Matt Kreger sitting in for Ghansham. Just wanted to follow-up on the raw materials front. Can you provide some added details and an update around what you're seeing in the raw material and other input cost basket across your business? Matthew KruegerVice President & Senior Equity Research Analyst at Baird00:31:58Maybe give us an updated outlook for the year? And any thoughts on if or how this latest round of tariffs impacts your cost base or maybe even how you're going to conduct your business? Any details there would be great. Thanks. Michael CasamentoEVP, Finance & CFO at Amcor00:32:15Yes, sure. I can help with that. It's Michael here. Look, from a raw material standpoint, the first half was really pretty benign. If you look at our numbers in the top line, in the revenue line, actually, the raw material number for the first half was flat. Michael CasamentoEVP, Finance & CFO at Amcor00:32:31So that tells you that the input costs overall were pretty flat for the first half. Q2 again was a similar trend to Q1. There was a little bit of pass through in Q2, but less than 1% in the top line and no impact in the earnings. And remember, we've got a broad base of goods across geographies, so they can move up and down at different rates. But generally, what we saw overall was the basket was pretty flat, perhaps down slightly. Michael CasamentoEVP, Finance & CFO at Amcor00:33:08And that included resins and liquids that were down in perhaps the low single digit range. And then there were some offsets with things like aluminum, which were up Michael CasamentoEVP, Finance & CFO at Amcor00:33:17what which were up in Michael CasamentoEVP, Finance & CFO at Amcor00:33:19the mid single digit range. As we then so pretty benign. If we look forward into Q3, it's about as far as we look out with any confidence. We'd say that it's probably a pretty similar view. Asia, Europe looking flat, perhaps in North America, some slight increases. Michael CasamentoEVP, Finance & CFO at Amcor00:33:41But overall, we'd expect the environment be relatively benign in Q3. And after that, we'll see what happens. From a tariff standpoint, I think our business is very regional. And in North America particularly, the level of imported goods is really very low and typically in specialty products that we can't get in this region. So from a tariff standpoint, that would be factored into the cost and then pass through. Michael CasamentoEVP, Finance & CFO at Amcor00:34:13So we don't really see a lot of impact on our business just because of the regional and local nature from any tariffs impacting the cost base. Peter KoniecznyChief Executive Officer at Amcor00:34:24And I may add to that. On the tariff side, 1st of all, everything that Michael said is very true. We're a very regional business. And if anything, we've become more regional given the experience from the past where long supply chains have essentially sort of created risk on the service levels to your customers. So we have even tried to shorten supply chains over the past. Peter KoniecznyChief Executive Officer at Amcor00:34:49And in terms of the ability to pass through tariffs, when you think about it, in some cases, we even have agreements with customers that would be based on indices that would allow us to pass on these additional costs. So I think we're in a spot where because we're regional, because we have some pass through opportunities, we feel we're not immune, but somewhat robust against the tariffs. Operator00:35:26Your next question comes from the line of Jacob Gokarnes with Jardens. Please go ahead. Jakob CakarnisDirector at Jarden Group Ltd00:35:32Hi, Peter. Hi, Michael. I just wanted to ask just about the trajectory in the Health business. So obviously some improvement there. It sounds like it's pharma that's still dragging on volumes. Jakob CakarnisDirector at Jarden Group Ltd00:35:44Just wondering as we move through the balance of the year, should the Berry merger complete? What's the exposure like to healthcare overall post merger? And do you think that the momentum that you're seeing gives you further confidence that you can drive that organic sales growth in the combined entity as you plan to please? Peter KoniecznyChief Executive Officer at Amcor00:36:06Yes. Well, thanks for that question because I'm a big healthcare fan. So I can take a step back and maybe help you sort of how we look at that. First of all, I believe that healthcare is a category that's a real gem in our portfolio. We've always said that from an anchor perspective and we're excited about the combination with Berry also because we can only strengthen that business. Peter KoniecznyChief Executive Officer at Amcor00:36:29Overall, when we combine the business, we're looking at about a $3,000,000,000 combined business in healthcare with really attractive exposures, which is also very complementary. On the Berry side, think about like multi component delivery devices, for example, inhalers that are being brought to market. And that is something that on the Amkra side, we have we do not have in our portfolio. So first of all, we believe that healthcare is a gem while it has been sort of challenged over the last couple of quarters because of pretty much significant destocking. You asked about the destocking. Peter KoniecznyChief Executive Officer at Amcor00:37:16We were essentially convinced that all of our categories have come to an end with destocking by the beginning of calendar 2024. The one that was left over really was healthcare because the destocking trend has started later and therefore lasted longer. As we then look at the 1st and the second quarter this fiscal year, we've seen definitely some destocking in the Q1 where the subcategory of medical had already returned to some growth, albeit small. But in pharma, we were pretty much challenged still with the destocking. We have seen in the Q2 medical further improve and strengthen. Peter KoniecznyChief Executive Officer at Amcor00:37:59On the pharma side, we've seen destocking abate. And again, we would now be in a spot where we'd say to keep things simple that destocking in healthcare is also over. Now realistically, there's probably going to be some lingering destocking that carries over in the Q3. I think I said that earlier today on a call on this call. But for the in the grand scheme of things, again, I think destocking is completely over. Peter KoniecznyChief Executive Officer at Amcor00:38:23With that said, healthcare will return back to growth. And we will get back to the historical growth rates 3%, 4% of healthcare over time. That will also take away the mix impact that we have in the translation to the bottom line. And overall, pretty excited with that going forward. Operator00:38:46Your next question comes from the line of Mike Roxanne with Chirrus Securities. Please go ahead. Michael RoxlandMD - Equity Research at Truist Securities00:38:53Thank you, P. K, Michael, Tracy, Dana for taking my questions. Michael RoxlandMD - Equity Research at Truist Securities00:38:59As you're proceeding through the Michael RoxlandMD - Equity Research at Truist Securities00:39:00due diligence process with Berry, is there anything that stands out that you weren't expecting upside, downside? My sense is that obviously some of the synergies do have some upside given your comments, PK, earlier. Then secondly, just given that growth, overall volume growth is slowly improving in the base Amicore business, is there anything you're doing maybe from a cost vantage point to help drive better profitability? Thanks. Peter KoniecznyChief Executive Officer at Amcor00:39:27Yes, Mike. So just got to think about the first question. There were 2 questions here. Can you guys help me with the first one? Tracey WhiteheadHead, IR at Amcor00:39:38Anything that stands out in the due diligence? Peter KoniecznyChief Executive Officer at Amcor00:39:40Yes. Thank you. So due diligence. Look, I would say there are no surprises on our side as we moved from announcing the deal a couple of months ago to where we're at today. But you got to remember, it's business as usual at this point in time, right? Peter KoniecznyChief Executive Officer at Amcor00:40:00So the data that we have available to look at is pretty much to a large extent really just the data that we had and that will significantly change only as we come to closing, which we expect to be in the middle of this calendar year, which has not changed versus what we've done before. So that's the answer to the first part of your question, is there anything positive or negative? We're pretty much in a spot where everything is as expected. And from a synergy perspective, you also mentioned that. And I think, yes, we are becoming more confident in the synergies. Peter KoniecznyChief Executive Officer at Amcor00:40:43So that is all positive. Now the second part of the question, I should have yes, Michael, do you want to take that? Michael CasamentoEVP, Finance & CFO at Amcor00:40:51Yes, I'll take that one, Pico. Sure. No, thanks for that part of the question, Mike. Yes, look on the cost side, we continue to focus on driving efficiency in our operations and our plants, managing the labor pool and flexing that to the volume as needed. We continue to look at the shift patterns and managing over time. Michael CasamentoEVP, Finance & CFO at Amcor00:41:13And we've also still got some residual benefits to come through from the restructuring programs that we had in place that we called out a couple of years ago in relation to offsetting some of those disposed earnings from Russia. So in the first half, we probably picked up about $7,000,000 benefit there and we've probably got another $7,000,000 or to come in the second half. So overall, it's a really strong cost focus and both operationally and still some benefits to come from the restructuring. So that's all factored into our guidance that we reaffirmed for the full year. Operator00:41:48Your next question comes from the line of John Pirtle with Macquarie. Please go ahead. John PurtellDivisional Director, Senior Analyst at Macquarie Group00:41:54Good day, Peter and Michael. Hope you're well. Look, just coming back to Berry, obviously, and thanks for the comments there on healthcare, Peter. But obviously, Berry globalizes your rigid business. John PurtellDivisional Director, Senior Analyst at Macquarie Group00:42:09I mean, what do you see as the sort of John PurtellDivisional Director, Senior Analyst at Macquarie Group00:42:11key benefits of that? And if you can also please touch on the growth outlook for closures and dispensing systems and what that potentially gives you? Thank you. Peter KoniecznyChief Executive Officer at Amcor00:42:23Thanks, John. So on the rigid business, you said it globalizes our rigid business. Let me be a little more specific about that and pull that apart, because I think it's really important. First of all, in terms of Quantum, our Rigids business, we summarize under the roof of Rigid Packaging, which is about a $3,000,000,000 business. And the Berry business has a containers and closures business, which is about a $7,000,000,000 business. Peter KoniecznyChief Executive Officer at Amcor00:42:57Hence, the combination will get us to a really scaled player and multi regions and that's different from what we have today. Now the key difference though is that we play only partly in the incomparable call it sub segments. When I dissect our rigid packaging business, it I would split it generally between the North American beverage business, which we discuss quite often because it's a scale business. It's in the beverage side. It sits in North America and it serves categories like isotonic ready to drink tea where we have some underlying challenges right now because it's a more discretionary category as we've discussed many times. Peter KoniecznyChief Executive Officer at Amcor00:43:45That's a scale volume driven business where we're very well positioned in North America on the Amcor side. The other part of that business is around specialty containers. That's a different business. It's also a scale business, but not as big as the North American beverage business, which serves a number of different categories and makes containers for those categories across the board. Now, the berry side of the containers business is much more comparable to the specialty containers business of Amcor. Peter KoniecznyChief Executive Officer at Amcor00:44:18That's where the complementarity comes in. In fact, berry doesn't do anything on the North American beverage business. They don't have exposure to that type of a segment. So we believe that is very positive for us because we were very interested in scaling up the specialty containers business as we call it which is very much aligned the berry business. And again on the berry side we have really good high value products. Peter KoniecznyChief Executive Officer at Amcor00:44:49When you think about it, it is the containers business of berry that actually brings along the healthcare exposure. And I talked about that earlier. Here we see the multi component more complex delivery systems on the healthcare side and there is other parts of the business that we likewise are attracted to. When you then go to the closure side of Berry, which is an addition to our business, particularly after we've divested our joint venture stake in the BerryCap joint venture, then you will find a nice exposure to dispensing systems and pumps that we likewise are very attracted to. So it is very complementary and it's not in the North American beverage space. Peter KoniecznyChief Executive Officer at Amcor00:45:41And therefore, we are pretty excited about the combination. Now you also asked us for our growth assumptions in the case of closures and dispensing systems. I think it's a little too early for me to give you like a concrete answer to that, that you can hold me to as we go forward. So I'll ask for a little more time for me to go back to that and confirm that on a later call. Operator00:46:16Your next question comes from the line of Keith Chow with MST Marquis. Please go ahead. Keith ChauResearch Analyst at MST Financial00:46:22Thanks so much for taking my follow-up question. Michael, just one for you. The last result, I think you guided to first half, second half split of 45, 55, which I think based on what's been achieved in the first half, that split implies the bottom of the guidance range. So I'm sorry to ask you a mathematical question, but the top end does imply sorry, the midpoint does imply a slightly greater skew to the second half. So given the top half now represents something more like $42,000,000 to $58,000,000 How are you thinking about that split going into the full year given what's happened in the first half or what's been achieved in the first half? Keith ChauResearch Analyst at MST Financial00:46:58Thank you. Michael CasamentoEVP, Finance & CFO at Amcor00:47:00Yes. Okay. Look, I think as I said in my comments, I mean, we are basing the phasing on the historical average is what we're expecting. And that's a range, right? I think when I talked Q1 last time around, it was approximately 25% to 55%, but it can vary on the margin. Michael CasamentoEVP, Finance & CFO at Amcor00:47:19I think, you know, as we've exited the first half, you know, it was right in line with our expectations. You know, volumes in that low single digit range, the margins were, you know, continue to expand and we saw the EPS, you know, growing at 5 percent. As we've kind of exited that, we looked into January and then looked at the outlook, we feel really confident in the second half, which is why we've reaffirmed our guidance today. And that as PK said, that implies the second half low single digit to mid single digit volume growth. That's going to be a key driver obviously of the outcome of the year. Michael CasamentoEVP, Finance & CFO at Amcor00:47:58And I think in terms of the range we've given you, the importance of the range, the volume particularly as we get into the higher seasonal seasonality of the business, particularly in Q4. I mean, we don't need a lot of volume improvement to really see strong leverage through the P and L, particularly in Q4 where the cost base is well covered off. That's the biggest quarter of the year, typically above 30% of earnings. And the other thing to take into account as well is clearly we're expecting the mix improvement in the second half as a result of the Healthcare business returning to growth and lapping that peak period of destocking last year. So from here, we sit we've reaffirmed guidance. Michael CasamentoEVP, Finance & CFO at Amcor00:48:43We feel pretty confident in that. And we'll update you in May as we work our way through the year. Operator00:48:50Ladies and gentlemen, this concludes our question and answer session. I will now turn the call back to Peter for closing remarks. Peter KoniecznyChief Executive Officer at Amcor00:48:58Yes. Thank you, Kate. Look, given the overall environment, we feel pretty confident and we feel pretty good about the quarter that we've delivered and I hope that came across. So again, we believe it's been a good quarter. The volume growth improved pretty confident in the second half and we've reaffirmed guidance on the back of that. Peter KoniecznyChief Executive Officer at Amcor00:49:22Thank you very much for your questions and your time. And I look forward or we look forward to having the opportunity to meet some of you at the upcoming conferences. Thank you very much. Operator00:49:34Ladies and gentlemen, that concludes today's call. Thank you and have a great day.Read moreParticipantsExecutivesTracey WhiteheadHead, IRPeter KoniecznyChief Executive OfficerMichael CasamentoEVP, Finance & CFOAnalystsAnthony PettinariAnalyst at CitigroupKeith ChauResearch Analyst at MST FinancialGeorge StaphosManaging Director at Bank of America Merrill LynchDaniel KangHead of Basic Industrials, Australian Equities Research at CLSA LimitedMatthew KruegerVice President & Senior Equity Research Analyst at BairdJakob CakarnisDirector at Jarden Group LtdMichael RoxlandMD - Equity Research at Truist SecuritiesJohn PurtellDivisional Director, Senior Analyst at Macquarie GroupPowered by